LSI Europe

Dimoveo Medical is a clinical-stage company developing an innovative method to clean/disinfect surfaces in the body using ultrasound-activated nanoparticles. Dimoveo's cleaning method is applied in open surgery to treat infections, This is done in parallel to the SOC DAIR procedure to reduce the failure rate. The initial application is in the orthopedic space for total knee arthroplasty. Want to learn more about Dimoveo Medical? Catch Yair Ramot’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

FaceHeart’s vision is to leverage its patented rPPG and AI solution to enhance the quality and accessibility of healthcare, contributing to the acceleration of the digital health industry. FaceHeart offers a non-invasive, seamless and contactless, video-based vital signs solution, FaceHeart Vitals™, that measures all the key vital signs, including Heart Rate, Blood Pressure, SpO2, and Respiration Rate as well as health indicators with a simple 45-second selfie video. As a Software as a Medical Device (SaMD), FH Vitals SDK is the only FDA-cleared rPPG technology that transforms your everyday devices with cameras into health monitors, enabling more affordable and high-quality healthcare anytime and anywhere. Want to learn more about FaceHeart? Catch Jerry S Chang’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Cryovasc utilizes cryoablation of the renal arteries to offer patients with hypertension an effective means to lower their blood pressure. The company has developed a catheter-based renal cryoablation system designed to perform renal denervation, a procedure aimed at reducing high blood pressure by disrupting overactive sympathetic nerves in the renal arteries. This approach utilizes cryoablation technology, which involves cooling tissue to interrupt nerve activity, offering a potentially safer alternative to existing methods that rely on heat-based ablation. Preclinical proof-of-principle has been successfully completed, and the company is in the process of publishing its findings in a high-impact medical journal. Want to learn more about Cryovasc? Catch Boris Keweloh’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

ChestPal™ has developed an AI neural network for accurate and reliable lung sound analysis with its ChestPal™ Pro device. The device is the only commercially available device to detect crackles and wheezes in the U.S. The device is designed to help clinicians arrive at a diagnosis accurately, quickly, and confidently, aiding in the timely treatment of life-threatening respiratory conditions, including pneumonia, asthma, and COPD. It enables lung exam sharing, making case escalation and referrals easy and convenient, especially in situations when a pulmonologist or other specialist is necessary and not located close to the patient. Want to learn more about ChestPal? Catch Steve Atkinson’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Throwback Tuesday #LSIEurope24 Last September, THERYQ CEO Ludovic Le Meunier was selected as an innovator for the 2024 LSI Europe annual event. The 2024 edition took place in Sintra, near Lisbon. While in Portugal, Ludovic had the opportunity to present our FLASH Radiotherapy solutions to a host of innovators and investors from the Life Science Intelligence network. Through his presentation, Ludovic introduced the key aspects of FLASH Radiotherapy that represent the very core of THERYQ's mission: pioneering the clinical translation of this technology. FLASH Radiotherapy is attracting significant attention in the world of radiation oncology, due to the potential it carries to change the way we treat cancer. This potential is reliant on the remarkable biological effect known as "FLASH", that can be observed when the dose is delivered in a fraction of a second at an Ultra-High Dose Rate (UHDR). Pre-clinical studies have repeatedly demonstrated that irradiation in these conditions maintains an equivalent level of tumor control as conventional radiotherapy, with lesser radiation-induced toxicity to healthy tissue surrounding the tumor. At THERYQ, we are developing a portfolio of linear accelerators capable of triggering the FLASH effect, with a view to integrating this technology into clinical routine - an innovation that could see entire treatments delivered in as little as a single session. A big thank you to the LSI team for a great event! 📰 Read more about THERYQ's mission on our website: https://lnkd.in/dwQvKTsf

Last month, Maculaser Ltd announced it is now part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, Chips JU)-funded initiative spanning 9 countries. This ambitious collaboration brings together leading research institutes and industrial partners to advance health care with cutting-edge photonics-based solutions. As part of this initiative, Maculaser is integrating innovative photonic technologies into PhotonMed’s treatment platform to enhance outcomes for patients with macular degeneration and other retinal conditions. Together, they aim to redefine the future of retinal care and improve the lives of millions. Maculaser is pioneering precision therapy for prevalent retinal diseases like Wet and Dry Age-Related Macular Degeneration (AMD). By carefully controlling temperature and retinal heating, the company’s technology ensures safe, consistent, and personalized treatments, reducing the risk of thermal damage to healthy tissue. Want to learn more about Maculaser? Catch Jani Tirronen’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

BEYEONICS™ Vision is empowering surgeons with augmented reality (AR) solutions that enhance and augment the information available to them in the operating room. The company is developing an exoscope-based digital imaging platform that transfers three-dimensional images of the surgical field to an AR headset. Beyeonics is currently developing its platform for ophthalmology (Beyeonics Vision), as well as neurosurgery and orthopedic surgery (BEYEONICS™ Surgical). Want to learn more about Beyeonics? Catch Burton Tripathi’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia. Want to learn more about Azalea Vision? Catch Enrique Vega’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Amber Implants BV is developing the VCFix Spinal System, a vertebral body augmentation system to improve pain control and stabilize the spine in patients suffering from vertebral compression fractures (VCFs). The company intends to improve the treatment of painful spinal fractures through improvements in mechanical performance, providing controlled restoration via more patient-specific implant customization, and offering superior stabilization that reduces the biomechanical load on the vertebral body and the spine. Want to learn more about Amber Implants? Catch Mohammad Ahmadi, PhD’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Summa Therapeutics is streamlining complex, below-the-knee procedures with the Finesse Injectable Angioplasty Balloon Catheter - a multifunctional catheter that combines crossing catheter, diagnostic catheter, and angioplasty balloon into a single device. People living with peripheral artery disease below the knee are at increased risk of lower limb amputation. Percutaneous revascularization is a time-intensive procedure that is often complicated by long-segment occlusions. Want to learn more about Summa Therapeutics? Catch Timothy Murphy’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is open for LSI Europe ‘25 this September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.